



RECEIVED

AUG 01 2002

JLB

AMENDMENTS

In the Specification:

Please remove the continuing application data paragraph, and replace it with the following paragraph:

-- The present application is a continuation-in-part of 09/587,583, filed June 2, 2000, now abandoned, which was a continuation-in-part of 09/434,313, filed October 25, 1999. --

In the Claims:

9. (Once Amended) The method of claim 8, wherein said tumor marker is PSA, ER, PR, CA-125, CA-199, CEA AFP, interferons, BRCA1, HER-2/neu, cytoxan, p53, endostatin, a monoclonal antibody or an antisense.

22. (Once Amended) The method of claim 21, wherein the ligand derivative is 99mTc-EC-glutamate pentapeptide.

Please add the following new claims, claims 52-55:

52. The method of claim 23, wherein the ligand is glucose or glucosamine.
53. The method of claim 23, wherein the ligand is deoxyglucose.
54. The method of claim 33, wherein the ligand is deoxyglucose.
55. The method of claim 35, wherein the ligand is deoxyglucose.